Oncology in Clinical Practice

Strona główna
Polska
Warsaw
Oncology in Clinical Practice

Dane kontaktowe, mapa i wskazówki, formularz kontaktowy, godziny otwarcia, usługi, oceny, zdjęcia, filmy i ogłoszenia od Oncology in Clinical Practice, Zdrowie i medycyna, Ulica Roentgena 5, Warsaw.

24/09/2026

A recent retrospective study investigated the prognostic and predictive significance of complete blood count-derived markers in patients with metastatic colorectal cancer treated with targeted biological agents.

Among 342 patients (369 treatment observations), lower hemoglobin levels and a lower lymphocyte-to-monocyte ratio (LMR) were independently associated with shorter overall survival. In contrast, NLR and PLR did not retain independent prognostic significance, and none of the evaluated inflammatory markers were associated with progression-free survival.

The authors conclude that these readily available blood-based markers may have prognostic value, while their role in predicting response or selecting a specific chemotherapy regimen or biologic agent remains uncertain.

Authors: Magdalena Krakowska, Sylwia Dębska-Szmich, Magdalena Grabiec, Emilia Olejnik, Roksana Pabich, Iga Kolus, Piotr Potemski

📖 Read the full article:
https://doi.org/10.5603/ocp.114424

18/09/2026

Adult colonic intussusception is a rare condition that may indicate an underlying malignancy. In this recent case report, a 20-year-old woman with intussusception of the ascending colon was diagnosed with mucinous adenocarcinoma and extensive adenomatous polyposis. Genetic testing subsequently identified a pathogenic germline APC mutation, confirming familial adenomatous polyposis (FAP).

The authors also review current recommendations for the management of FAP, including surgical treatment, lifelong endoscopic surveillance, genetic counseling, and screening of at-risk family members.

Authors: Julia Ciesielska, Szymon Niemiec, Andrzej Guzik, Joanna Kobak

📖 Read the full article:
https://doi.org/10.5603/ocp.112828

16/09/2026

A recent case report and literature review describes a 42-year-old woman with metastatic malignant melanoma and a right atrial metastasis. Retesting of metastatic tissue identified a BRAF V600E mutation after testing of archival primary tumor tissue was nondiagnostic, enabling targeted treatment with dabrafenib and trametinib. BRAF/MEK inhibitor therapy resulted in complete resolution of the right atrial mass on transthoracic echocardiography, although cardiac involvement later recurred with disease progression.

Authors: Aleksander Gorzeń, Tomasz Świtaj, Paweł Rogala, Hanna Koseła-Paterczyk, Karolina Sosnowska, Paweł Teterycz, Katarzyna Kozak, Piotr Rutkowski, Anna M. Czarnecka

📖 Read the full article:
https://doi.org/10.5603/ocp.112654

02/09/2026

This recent case report describes rapidly progressive and fatal pulmonary hypertension occurring in a 39-year-old woman with ALK-positive non-small cell lung cancer during long-term treatment with alectinib.

Pulmonary hypertension developed after 17 months of alectinib therapy, despite radiographically stable disease and no significant residual thromboembolic burden on CT pulmonary angiography. The authors highlight a possible rare pulmonary vascular toxicity associated with ALK inhibitors, while emphasizing that a causal association with alectinib could not be definitively confirmed.

Authors: Jan Chmielewski, Elżbieta Czekajska-Chehab, Edyta Opalińska, Izabela Chmielewska, Paweł Krawczyk, Janusz Milanowski

📖 Read the full case report:
https://doi.org/10.5603/ocp.113041

24/08/2026

This recent case report describes an exceptionally rare occurrence of advanced squamous cell lung cancer in a 25-year-old man with a history of short-term asbestos exposure and light smoking.

The disease was diagnosed at stage IVB with multiple bone and central nervous system metastases and progressed rapidly despite radiotherapy and first-line chemoimmunotherapy. The authors emphasize that lung cancer should be considered even in very young adults and that persistent respiratory symptoms warrant timely diagnostic evaluation.

Authors: Tobiasz Wróblewski, Katarzyna Ostrowska, Paulina Wesołowska, Filip K. Gajewski, Beata Gryglicka, Karolina Dubiel-Kosikowska, Paweł Krawczyk

📖 Read the full case report:
https://doi.org/10.5603/ocp.113154

13/08/2026

A recent narrative review explores the efficacy of immune checkpoint inhibitors in rare oncogene-driven non-small cell lung cancer. BRAF-mutated NSCLC appears to derive the greatest benefit from immunotherapy, while ICI monotherapy shows more limited activity in MET exon 14, HER2, RET, and EGFR exon 20-altered tumors. Although chemoimmunotherapy may improve outcomes in selected patients, targeted therapies remain the preferred treatment strategy for most molecular subgroups.

Authors: Paulina Kalman, Magdalena Knetki-Wróblewska

📖 Read the full article:
https://doi.org/10.5603/ocp.113505

10/08/2026

This recent case report describes a rare pattern of dynamic HER2 discordance in breast cancer, with HER2 status changing over time and following systemic treatment. HER2 amplification was identified in the residual breast tumor after chemotherapy, while contralateral axillary metastases remained HER2-negative.

The case highlights the potential impact of intratumoral heterogeneity, clonal selection, and sampling variability, emphasizing the importance of repeat biomarker reassessment in recurrent or residual breast cancer.

Authors: Paulina Kalman, Ewa Szombara, Zbigniew Nowecki, Monika Durzyńska, Katarzyna Pogoda

📖 DOI: https://doi.org/10.5603/ocp.111460

29/07/2026

A recent narrative review summarizes the pathophysiology, clinical impact and current treatment strategies for cancer cachexia, a multifactorial syndrome associated with involuntary weight loss, skeletal muscle wasting, systemic inflammation and progressive functional impairment.

The authors emphasize that single-agent therapies provide limited benefits. Early, individualized multimodal management combining nutritional support, resistance and aerobic exercise, pharmacotherapy and emerging targeted therapies appears to offer the greatest potential to preserve muscle mass and physical function, improve treatment tolerance and maintain quality of life.

Nutritional strategies enriched with omega-3 fatty acids and high-protein formulas may support muscle preservation, while agents such as anamorelin provide partial symptomatic benefits. Emerging approaches targeting GDF-15, IL-6 and myostatin or activin signaling are promising, but require further clinical validation.

Authors: Zuzanna Kościów, Klaudia Gutowska

📖 DOI:
https://doi.org/10.5603/ocp.113525

28/07/2026

Prostate cancer in Poland, 2013–2023

A recent nationwide analysis shows that the age-standardized incidence of prostate cancer in Poland increased substantially between 2013 and 2023, while age-standardized mortality remained broadly stable. Despite a lower incidence than the EU-27 average, Poland continues to record considerably higher mortality, indicating a persistent gap in outcomes.

The study also documents the modernization of diagnostic pathways, including an approximately four-fold increase in MRI use, and a shift in first-line treatment: in 2023, surgery accounted for 53.0% of first treatments, compared with 40.8% for radiotherapy.

Authors: Michał Seweryn, Paweł M. Potocki, Janusz Ligeza, Anna B. Łuc-Seweryn, Paweł Koczkodaj

DOI: https://doi.org/10.5603/ocp.113452

27/07/2026

Nectins and nectin-like molecules are emerging as important players in cancer biology, immune regulation, and targeted therapy.

In this recent review, the authors summarize their expression, biological functions, prognostic relevance, and therapeutic implications in melanoma, lung cancer, and renal cell carcinoma. Nectin-4 and the CD155/TIGIT axis currently represent the most therapeutically actionable targets, while Nectin-1 has a dual role in melanoma as a metastasis suppressor and an entry receptor for HSV-based oncolytic therapy.

The review also discusses antibody-drug conjugates such as enfortumab vedotin, TIGIT-directed combination strategies, oncolytic virotherapy, and emerging CAR-T-cell approaches.

Authors: Anna M. Czarnecka, Michał Nizio, Anna Szumera-Ciećkiewicz, Magdalena Knetki-Wróblewska, Ewa Bartnik, Piotr J. Błoński, Piotr Rutkowski

Adres

Ulica Roentgena 5
Warsaw
02-781

Strona internetowa

https://journals.viamedica.pl/oncology_in_clinical_practice, https://www.researchgate.net/journal/Oncology-in-Clinical-P

Powiadomienia

Bądź na bieżąco: wyślemy Ci e-mail, gdy Oncology in Clinical Practice opublikuje nowości i promocje. Twój adres e-mail nie zostanie wykorzystany do żadnego innego celu, a subskrypcję możesz anulować w dowolnym momencie.